• InvestorsInvestors
  • PatientsPatients
  • PressPress
  • Chercher dans le siteChercher dans le site

Select your language

  • FR
Alzprotect Alzprotect
  • Company
    • About the Company
    • Team
    • Partners
    • Careers
  • Expertise
    • Therapeutic Strategy
    • Research & Development
    • Publication
  • Pipeline
  • News
  • Contact
  • InvestorsInvestors
  • PatientsPatients
  • PressPress
  • Chercher dans le siteChercher dans le site

Select your language

  • FR

News

Laboeatory

Alzprotect announces the WHO approval of generic name Ezeprogind for the « first-in-Class » AZP2006 clinical stage drug

Read more …

Brand identity: Alzprotect changes its signature

 

Read more …

Interview Biotech Finances

Interview Biotech Finances  25/06/2020

 

Read more …

Alzprotect obtains authorization to start a Phase 2a clinical trial in PSP

 

Read more …

Page 2 of 2

  • 1
  • 2
  • Alzprotect
  • Expertise
  • AZP2006
  • News
  • Investisseurs
  • Patients
  • Press

Alzprotect

85 Rue Nelson Mandela
59120 Loos
France
Tel. +33 972 649 757

Contact

  • Conditions générales d'utilisation
  • Confidentialité

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Ok Decline
More information